15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Cardiff Oncology Inc, 1 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $10.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.00 sits 443% above the current $1.10. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy120%
Hold480%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Cardiff Oncology Inc.
As of Sep, 1 of 5 firms rate CRDF a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRDF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.20 – $-0.09 · 5 analysts · +29% YoY
Next period, 5 analysts expect Cardiff Oncology Inc to earn $-0.14 a share (range $-0.20 – $-0.09), versus $-0.11 a year earlier. Full-year consensus is $-0.56, growing to $-0.60 the year after.
REVENUE · NEXT QUARTER
$83.3K
Range $0 – $155.0K · 5 analysts · -66% YoY
Revenue is expected to reach $83.3K (range $0 – $155.0K), -65.7% year-over-year. Full-year consensus is $286.8K, rising to $265.0K next year.
Top analysts covering Cardiff Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRDF.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Hold
No targeton CRDF
Overall win rate
41%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #272
Buy
$10.00+805.0% to target
Overall win rate
41%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$13.00+1076.5% to target
Overall win rate
36%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$6.00+443.0% to target
Overall win rate
29%
+ Follow
#5
RL
Robert LeBoyer
Noble Financial
Buy
$12.00+986.0% to target
Coverage
—
+ Follow
CRDF stock forecast FAQ
What is CRDF's average 12-month price target?+
The 2 analysts with a live target average $6.00 for Cardiff Oncology Inc over the next 12 months, ranging from a $10.00 high to a $2.00 low.
Is CRDF stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 1 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRDF?+
The Street-high target is $10.00, and the Street-low is $2.00 (Craig-Hallum). The average of all 2 active targets is $6.00.
How many Wall Street analysts cover CRDF?+
5 analysts have an active rating on Cardiff Oncology Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRDF?+
Among analysts who currently cover CRDF, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #199). Their current call is Hold.
What is Cardiff Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.20 – $-0.09) across 5 analysts. Full-year EPS is projected at $-0.56, rising to $-0.60 the following year.
How much revenue is Cardiff Oncology Inc expected to report next quarter?+
Consensus revenue is $83.3K (range $0 – $155.0K). Full-year revenue is projected at $286.8K, growing to $265.0K next year.
Have analysts been upgrading or downgrading CRDF lately?+
As of Sep, 1 of 5 firms rate CRDF a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRDF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
